CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx Q2 results miss estimates, co revises FY 2022 revenue guidance https://seekingalpha.com/news/3867475-caredx-q2-results-miss-estimates-co-revises-fy-2022-revenue-guidance • CareDx press release (NASDAQ:CDNA): Q2 Non-GAAP EPS of -$0.13 misses by $0.02. • Revenue of $80.6M (+8.6% Y/Y) misses by $1.25M. • Sees FY 2022 revenue of $325 million to $335 million vs. previous forecast of $330M to $350M. The consensus revenue estimate is $337.96M. 

CareDx Reports Second Quarter 2022 Results https://www.businesswire.com/news/home/20220804005967/en/CareDx-Reports-Second-Quarter-2022-Results

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care https://www.businesswire.com/news/home/20220802005596/en/CareDx-Launches-Personalized-AlloHome-Patient-Monitoring-Solution-to-Augment-Pre--and-Post-Transplant-Care AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions

https://www.businesswire.com/news/home/20220602005408/en/CareDx-Leads-Transplant-Innovation-with-AiKidney-an-AI-Clinical-Decision-Support-Tool-for-Predicting-Allograft-Rejection-Risk

https://www.globenewswire.com/news-release/2022/05/24/2449070/31386/en/CareDx-Receives-CE-Mark-for-AlloSeq-HCT-for-Use-in-Hematopoietic-Cell-Transplantation.html

https://www.globenewswire.com/news-release/2022/05/17/2444754/31386/en/In-CareDx-Initiated-IP-Litigation-Against-Natera-Natera-Now-Drops-1-of-2-Patents-Originally-Asserted-Against-CareDx.html

CareDx Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/05/2437284/31386/en/CareDx-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/05/2436571/31386/en/CareDx-Validates-Clinical-Performance-of-AlloMap-Kidney-to-Comprehensively-Assess-Transplant-Rejection.html

https://www.globenewswire.com/news-release/2022/04/14/2422640/31386/en/CareDx-Reports-Over-200-000-Heart-Transplant-Patient-Results-Served.html CareDx Reports Over 200,000 Heart Transplant Patient Results Served CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States

https://www.globenewswire.com/news-release/2022/04/11/2419896/31386/en/CareDx-the-Leading-Sponsor-of-UNOS-Transplant-Management-Forum-Demonstrates-the-Value-of-Digital-Solutions-to-Improve-Pre-Transplant-Patient-Referral-and-Waitlisting-Workflow.html

https://www.globenewswire.com/news-release/2022/03/30/2412689/31386/en/CareDx-Partners-with-the-European-Society-for-Organ-Transplantation-to-Provide-Clinical-Evidence-Supporting-the-Use-of-AlloSeq-cfDNA-with-European-Transplant-Healthcare-Professiona.html

https://www.globenewswire.com/news-release/2022/03/24/2409242/0/en/CareDx-s-AlloCare-App-Now-Integrated-with-TxAccess-to-Help-Pre-Transplant-Patients-Navigate-the-Waitlist-Process.html

CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; ... https://www.bakersfield.com/ap/news/caredx-wins-44-9m-in-damages-in-false-advertising-trial-against-natera-natera-intentionally/article_8849930e-0d01-591f-b643-3ba8c4035548.html

CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients https://www.globenewswire.com/news-release/2022/03/03/2396118/31386/en/CareDx-Announces-Cibiltech-Initiates-CIBIL-Study-Using-iBox-Artificial-Intelligence-to-Monitor-Kidney-Transplant-Patients.html Results from CareDx’s OKRA Study and Cibiltech’s CIBIL Study will Demonstrate Clinical Utility of iBox for Transplant Patient Management

https://www.globenewswire.com/news-release/2022/03/02/2395224/31386/en/CareDx-Partners-with-the-National-Kidney-Foundation-to-Advocate-for-Kidney-Transplant-Patients.html

CareDx Reports Fourth Quarter and Full Year 2021 Results https://www.streetinsider.com/dr/news.php?id=19673878&gfv=1